Brenda Burnham

Brenda Burnham is an experienced scientist in the field of gene therapy and vector development, currently serving as a Scientist in Vector Development/Manufacturing at Homology Medicines Inc. since February 2016, focusing on next-generation gene editing and therapy technologies for rare diseases. Prior to this role, Brenda Burnham spent over a decade at Genzyme Corporation, where responsibilities included producing research and pre-clinical grade Adeno-Associated Virus (rAAV) and overseeing analytical methods for vector quality. Brenda Burnham's extensive background also includes positions at MatTek Corporation, UMASS Medical School, and Harvard Medical School, contributing to areas such as tissue model development, diabetes research, and monoclonal antibody generation. Brenda Burnham holds a Bachelor of Science in Biochemical Science from the University of Vermont.